Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 SEP 7 ... molecules PTK2, TGFBR2 and CD9 overexpressed during advanced bone marrow remodelling in primary myelofibrosis.' "Primary myelofibrosis (PMF) is a ...
2009 JUL 27 ... in 100 MPN, including 24 essential thrombocythemia-(ET), 46 polycythemia vera-(PV), 26 primary myelofibrosis-(PMF), four myelodysplastic (MDS)/MPN-and 20 control reactive bone marrow cases, and ...
2009 JUL 6 ... The three main Ph(-) MPDs are polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). The key features of these Ph(-) MPDs are an increased red blood cell mass in PV, ...
2009 OCT 12 ... According to a study from Florence, Italy, "A total of 186 patients with primary myelofibrosis (PMF) were genotyped for JAK2V617F at diagnosis aimed at analyzing the correlation of ...
2009 JUN 15 ... Incyte’s request for a Special Protocol Assessment (SPA) for INCB18424 for patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia ...
2009 AUG 3 ... a pivotal Phase III trial for its lead JAK1/JAK2 Inhibitor, INCB18424, in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia ...
2009 AUG 10 ... is expected to begin patient enrollment in August and involve 240 patients with primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (PPV-MF) and post essential thrombocythemia ...
2009 JUL 13 ... the findings with those observed in other fibrotic bone marrow disorders such as primary myelofibrosis and metastatic malignancy. Histochemistry and immunohistochemistry were used to ...
2009 JUL 6 ... According to a study from South Korea, "Primary myelofibrosis (PMF) is a myeloproliferative disorder characterized by bone marrow fibrosis or ...
2009 NOV 9 ... (MPDs), which include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Nonetheless, genetic defects have not yet been identified in about 40% of ET and ...
2009 JUL 20 ... from the United States, "Managing patients with myelofibrosis (MF), either those with primary MF or those whose MF has evolved from antecedent polycythemia vera or essential ...
2009 JUN 22 ... factors in myeloid malignancies, they are not included in current prognostic scores for primary myelofibrosis (PMF). To determine their relevance in PMF, we retrospectively examined the impact of ...
2009 OCT 5 ... New investigation results, 'The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan,' are detailed in a study published in ...
2009 JUL 6 ... clinical indication for BM biopsy examination in cases with tumor BM metastasis, (3) the primary sites of the metastatic tumors, and (4) the advantage of plastic-embedded biopsy ... was 74.3%. All the 101 sections with metastatic tumors showed various degrees of myelofibrosis. We concluded that the routine BM biopsy examination is helpful in detecting insidious ...
2009 OCT 12 ... researchers concluded: "TET2 mutations were mainly observed (10 of 12) in patients with primary myelofibrosis or patients with polycythemia vera or essential thrombocythemia who secondarily evolved ...
2009 NOV 16 ... "The abnormal trafficking of CD34(+) cells is a unique characteristic of primary myelofibrosis (PMF). We have further studied the behavior of PMF CD34(+) cells by examining their ...
2009 SEP 21 ... Peripheral blood (PB) CD34(+) cells from patients with polycythemia vera (PV) and primary myelofibrosis (PMF) generated in vitro significantly fewer mast cells (MCs) than normal PB CD34(+) ...
2009 JUN 29 ... activating W515L mutation in the thrombopoietin receptor (MPL) has been identified in primary myelofibrosis and essential thrombocythemia. MPL belongs to a subset of the cytokine receptor ...
2009 NOV 2 ... 28 patients, followed by a dose-confirmation phase that enrolled 31 patients. The primary goals of this open-label, dose-escalation study included identification of a maximum ... of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myelofibrosis. There are no currently approved specific therapies for myelofibrosis (MF), ...
